Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Rizzo

Showing results (41-50 of 381) with videos related to

Pageof 39
Sort By:
European Urology Oncology|October 30, 2020
Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. In press. https://doi.org/10.1158/1078-0432.ccr-20-2063Alessandro Rizzo, Veronica Mollica, Francesco Massari
The New England Journal of Medicine|September 1, 2021
Adjuvant Nivolumab in Muscle-Invasive Urothelial CarcinomaVeronica Mollica, Alessandro Rizzo, Francesco Massari
The Lancet. Oncology|July 1, 2021
Second-line FOLFOX chemotherapy for advanced biliary tract cancerGiovanni Brandi, Giorgio Frega, Alessandro Rizzo
European Urology Focus|January 31, 2021
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysisAlessandro Rizzo, Veronica Mollica, Francesco Massari
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|November 7, 2014
Effect of individual behavior on epidemic spreading in activity-driven networksAlessandro Rizzo, Mattia Frasca, Maurizio Porfiri
European Urology Oncology|July 13, 2020
Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2020.2218: SAVOIR: From Own Goal to Winning Goal?Veronica Mollica, Alessandro Rizzo, Francesco Massari
JAMA Oncology|May 13, 2021
Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate CancerAlessandro Rizzo, Veronica Mollica, Francesco Massari
European Urology Oncology|May 17, 2021
Re: Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021;384:1125-35Alessandro Rizzo, Veronica Mollica, Francesco Massari
JAMA Oncology|August 26, 2021
Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing IntegrityAlessandro Rizzo, Veronica Mollica, Francesco Massari
Journal of Theoretical Biology|January 26, 2016
A network model for Ebola spreadingAlessandro Rizzo, Biagio Pedalino, Maurizio Porfiri
Pageof 39

Showing results (41-50 of 381) with videos related to

Sort By:
Pageof 39
European Urology Oncology|October 30, 2020
Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. In press. https://doi.org/10.1158/1078-0432.ccr-20-2063Alessandro Rizzo, Veronica Mollica, Francesco Massari
The New England Journal of Medicine|September 1, 2021
Adjuvant Nivolumab in Muscle-Invasive Urothelial CarcinomaVeronica Mollica, Alessandro Rizzo, Francesco Massari
The Lancet. Oncology|July 1, 2021
Second-line FOLFOX chemotherapy for advanced biliary tract cancerGiovanni Brandi, Giorgio Frega, Alessandro Rizzo
European Urology Focus|January 31, 2021
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysisAlessandro Rizzo, Veronica Mollica, Francesco Massari
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|November 7, 2014
Effect of individual behavior on epidemic spreading in activity-driven networksAlessandro Rizzo, Mattia Frasca, Maurizio Porfiri
European Urology Oncology|July 13, 2020
Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2020.2218: SAVOIR: From Own Goal to Winning Goal?Veronica Mollica, Alessandro Rizzo, Francesco Massari
JAMA Oncology|May 13, 2021
Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate CancerAlessandro Rizzo, Veronica Mollica, Francesco Massari
European Urology Oncology|May 17, 2021
Re: Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021;384:1125-35Alessandro Rizzo, Veronica Mollica, Francesco Massari
JAMA Oncology|August 26, 2021
Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing IntegrityAlessandro Rizzo, Veronica Mollica, Francesco Massari
Journal of Theoretical Biology|January 26, 2016
A network model for Ebola spreadingAlessandro Rizzo, Biagio Pedalino, Maurizio Porfiri
Pageof 39